- Home
- RYTM vs PK Comparison
RYTM vs PK Comparison
Compare RYTM & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYTM | PK |
|---|---|---|
| Founded | 2008 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 2.0B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | RYTM | PK |
|---|---|---|
| Price | $111.98 | $10.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 11 |
| Target Price | ★ $127.31 | $11.45 |
| AVG Volume (30 Days) | 1.0M | ★ 3.7M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 9.16% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $174,334,000.00 | ★ $2,541,000,000.00 |
| Revenue This Year | $47.34 | $0.11 |
| Revenue Next Year | $57.18 | $2.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.92 | N/A |
| 52 Week Low | $45.91 | $8.27 |
| 52 Week High | $122.20 | $15.12 |
Technical Indicators
Market Signals| Indicator | RYTM | PK |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 55.21 |
| Support Level | $109.99 | $10.66 |
| Resistance Level | $115.05 | $11.03 |
| Average True Range (ATR) | 5.20 | 0.30 |
| MACD | 0.60 | 0.04 |
| Stochastic Oscillator | 53.93 | 79.58 |
Price Performance
Historical ComparisonAbout RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.